SCHEMBL7188524

SCHEMBL7188524

Cc1cc(C)c(C(=O)[PH](=O)c2c(C)c(C)c(C(=O)c3ccccc3)c(C)c2C)c(C)c1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.38
NPSR1 Q6W5P4 3/20 0.38
HPGD P15428 2/20 0.38
LMNA P02545 2/20 0.38
MEN1 O00255 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MCOLN3 Q8TDD5 1/20 0.38
HTT P42858 1/20 0.38
ALDH1A1 P00352 3/20 0.37
MAPT P10636 1/20 0.37
BCL2L1 Q07817 1/20 0.36
ATM Q13315 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GFER P55789 1/20 0.35
GRM6 O15303 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180036 0.97 KMT2A (0.37) KMT2ANPSR1HPGDLMNAMEN1
SCHEMBL7180474 0.89 HTT (0.38) KMT2ANPSR1HPGDLMNAMEN1
SCHEMBL7178033 0.88 HTT (0.40) KMT2ANPSR1HPGDLMNAMEN1
SCHEMBL7190429 0.88 LMNA (0.38) LMNAHTTALDH1A1MAPTBCL2L1
SCHEMBL7174636 0.87 NPSR1 (0.37) KMT2ANPSR1HPGDLMNAMEN1
SCHEMBL7181623 0.86 HTT (0.37) KMT2ANPSR1HPGDLMNAMEN1
SCHEMBL7177292 0.86 HTT (0.38) KMT2ANPSR1HPGDLMNAMEN1
SCHEMBL7175881 0.85 LMNA (0.36) LMNAHTTALDH1A1MAPTBCL2L1
SCHEMBL7182193 0.85 HPGD (0.37) KMT2ANPSR1HPGDLMNAMEN1
SCHEMBL7180492 0.84 NPSR1 (0.40) KMT2ANPSR1HPGDLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885NPSR1 2669/4885HPGD 3983/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885NPSR1 3007/4885HPGD 4041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.